🏛️ Company factsSEC filings + FINRA official data
Annual revenue $94.2B · latest quarter up 6.6% YoY · profitable (FY net income $26.8B) · short activity within its normal range.
FY revenue
$94.2B
2025-12
Latest Q YoY
+6.6%
Gross margin
67.9%
FY net income
$26.8B
Diluted EPS
$11.13
Short volume
57.1%
20d avg 52.1% · normal
🐋 5%+ ownership filings (last 180d)
The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.
- 2026-05-01passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
- 2026-03-26passive (13G)VANGUARD GROUP INC
🎯 Market expectations
Expectation reliability Medium · 59/100Nasdaq analyst consensus · the pre-news baseline
- Jun 2026$2.90 vs $2.84+2.11%
- Mar 2026$2.70 vs $2.67+1.12%
- Dec 2025$2.46 vs $2.43+1.23%
- Sep 2025$2.80 vs $2.77+1.08%
The takeaway
It has tracked consensus closely — no systematic over- or under-shooting.
Analyst estimates, not our forecast · not investment advice
What's moving this stock lately
1 direct · 0 2nd-order · 0 thematicRanked by impact strength · strength = estimated move × freshness decay (shorter-lived effects decay faster)
With $94.2B revenue and 67.9% gross margin, being named bolsters its image as a defensive healthcare leader
Also named: KO · PG · CL · PEP
🕰️ Price × news · engine report card
Drag to pan, scroll to zoom · real daily bars and volume
📜 Call history (newest first
9 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view
Sign up · free 7-day trial →Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.
Sign up · free 7-day trial →